Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

Mariangela Russo*, Mengnuo Chen, Elisa Mariella, Haoning Peng, Sumaiyah K. Rehman, Elena Sancho, Alberto Sogari, Tzen S. Toh, Nathalie Q. Balaban, Eduard Batlle, Rene Bernards, Mathew J. Garnett, Matthew Hangauer, Eleonora Leucci, Jean Christophe Marine, Catherine A. O’Brien, Yaara Oren, E. Elizabeth Patton, Caroline Robert, Susan M. RosenbergShensi Shen, Alberto Bardelli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The emergence of drug resistance is the most substantial challenge to the effectiveness of anticancer therapies. Orthogonal approaches have revealed that a subset of cells, known as drug-tolerant ‘persister’ (DTP) cells, have a prominent role in drug resistance. Although long recognized in bacterial populations which have acquired resistance to antibiotics, the presence of DTPs in various cancer types has come to light only in the past two decades, yet several aspects of their biology remain enigmatic. Here, we delve into the biological characteristics of DTPs and explore potential strategies for tracking and targeting them. Recent findings suggest that DTPs exhibit remarkable plasticity, being capable of transitioning between different cellular states, resulting in distinct DTP phenotypes within a single tumour. However, defining the biological features of DTPs has been challenging, partly due to the complex interplay between clonal dynamics and tissue-specific factors influencing their phenotype. Moreover, the interactions between DTPs and the tumour microenvironment, including their potential to evade immune surveillance, remain to be discovered. Finally, the mechanisms underlying DTP-derived drug resistance and their correlation with clinical outcomes remain poorly understood. This Roadmap aims to provide a comprehensive overview of the field of DTPs, encompassing past achievements and current endeavours in elucidating their biology. We also discuss the prospect of future advancements in technologies in helping to unveil the features of DTPs and propose novel therapeutic strategies that could lead to their eradication.

Original languageEnglish
Pages (from-to)694-717
Number of pages24
JournalNature Reviews Cancer
Volume24
Issue number10
DOIs
StatePublished - Oct 2024

Fingerprint

Dive into the research topics of 'Cancer drug-tolerant persister cells: from biological questions to clinical opportunities'. Together they form a unique fingerprint.

Cite this